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Abstract  
AIM: The primary objective of the study was to evaluate the overall survival of women with advanced stage 
(Stage IIIA-IV) high-grade serous ovarian cancer in Macedonia 
MATERIALS AND METHODS: The study was a cross-sectional medical record review of patients diagnosed with 
advanced stage HGSC. Patients were deemed eligible for inclusion if they were diagnosed with an advanced 
stage (Stage IIIA-IV) HGSC of the ovary, fallopian tube or peritoneum between 2009 and 2015.  The data were 
analyzed in a descriptive fashion and summary statistics were provided, as appropriate. Survival was calculated 
using the Kaplan-Meier method. 
RESULTS: A total of 81 eligible patients were identified and included in the study. The average overall survival in 
the studied cohort was 46.59 months (95%CI = 39.11-54.06). Patients that were optimally debulked and patients 
that had a platinum-free interval larger than 12 months had significantly longer survival in the current series (p < 
0.001). 
CONCLUSION: the average overall survival of advanced stage HGSC patients in the studied series was 46.59 
months (95%CI = 39.11-54.06). Patients aged 65 years or younger tended to live approximately ten months 
longer than patients older than 65 years, but this difference was not statistically significant. There was no 
difference in HGSC survival in the groups of patients with grade 2 and grade 3 disease. However, optimal surgical 
debulking and platinum sensitivity were associated with significantly better overall survival. 
 
 
 
 
Introduction 
 
Epithelial ovarian cancer is the fifth most 
common cancer-related cause of death in women in 
the developed countries with no significant 
improvement in the survival rates in the last three 
decades in spite of numerous scientific efforts [1]. It is 
estimated that in Europe alone, a total of 65538 new 
cases and 42704 deaths were registered in 2012 [2]. 
Early stage disease (i.e. disease localised to the 
ovaries) is associated with an overall 5-year survival 
rate of over 90%; however, only a small proportion of 
patients (approximately 15%) present with early 
disease [3]. On the other hand, five-year survival rates 
for patients with metastatic ovarian cancer are 
currently estimated to be less than 30% [3]. The 
current consensus is that all patients with advanced or 
metastatic ovarian cancer should be treated with 
surgical debulking and subsequent systemic 
chemotherapy. First-line chemotherapy is usually a 
platinum-based regimen (i.e. carboplatin with or 
without paclitaxel) [4]. Most ovarian cancer patients 
have high initial response rates, but eventually, recur 
and require further treatment.  
Tumor relapses can be classified, by the time 
interval between the completion of the initial platinum-
based chemotherapy regimen and the diagnosis of 
the recurrence, as platinum-sensitive (recurrence 
detected after six months or longer) or platinum-
resistant (recurrence detected within six months). 
Patients with platinum-resistant tumours have poorer 
response rates to the subsequent chemotherapy 
regimens and, consequently, shorter overall survival 
[5]. Ovarian cancer may occur at any age, but most 
patients are older than 50 years at the time of 
diagnosis. Advanced age at the time of diagnosis is 
associated with poorer outcomes: the 5-year survival 
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rate drops to below 30% in patients older than 65 
years [6]. This is probably because older patients 
have at least one underlying comorbidity which is 
thought to be associated with poorer prognosis [7, 8].  
The most common histological type of ovarian 
cancers is serous cancers. Once thought to arise from 
the ovarian surface epithelium, recent pathological 
and molecular studies have shifted the paradigm of 
the origin of serous epithelial ovarian cancers towards 
non-ovarian tissues, namely the secretory cells of the 
distal parts of the fallopian tubes [9]. 
Tumor grade, as a pathological index of 
cellular aberration, is an additional prognostic factor 
for serous ovarian cancer. It is widely accepted that 
low-grade tumours occur from tumours of borderline 
malignancy that acquire activating mutations in the 
member of the RAS pathway (KRAS, BRAF, and 
ErbB2) [10]. On the other hand, such mutations of the 
RAS pathway are rarely identified in high-grade 
serous cancers.  
High-grade serous carcinomas (HGSCs) 
remain the most aggressive subtype of ovarian 
cancers and account for the vast majority of advanced 
stage cases [11].  
To our knowledge, there is virtually no 
published data on the survival of advanced stage 
HGSC patients in the Republic of Macedonia. The 
primary objective of the study was to evaluate the 
overall survival of women with advanced stage (Stage 
IIIA-IV) high-grade serous ovarian cancer in 
Macedonia.  
 
 
Material and Methods 
 
The study was a cross-sectional medical 
record review of patients diagnosed with advanced 
stage HGSC. We searched the hospital registers of 
the University Clinic for gynaecology and obstetrics 
and the University clinic for oncology and radiotherapy 
at the University "Ss. Cyril and Methodius" in Skopje, 
Macedonia. Both participating academic centres are 
tertiary healthcare where the majority of these patients 
in Macedonia are referred for treatment. Patients were 
deemed eligible for inclusion if they were diagnosed 
with an advanced stage (Stage IIIA-IV) HGSC of the 
ovary, fallopian tube or peritoneum between 2009 and 
2015. Patients with non-serous histology, borderline 
tumours, early-stage and low-grade serous subtypes, 
as well as patients with insufficient follow-up data 
were excluded from the study. Clinical and disease 
characteristics, including age at diagnosis, stage, 
residual disease after primary surgery, treatment 
history and recurrence history, were collected from the 
available medical records. All primary surgeries were 
performed at the Department of gynecologic oncology 
at the University clinic of gynaecology and obstetrics, 
and all patients received adjuvant chemotherapy at 
the University clinic of oncology and radiotherapy. 
Cytoreductive surgery was characterised as optimal if 
there was ≤1 cm of residual disease and suboptimal if 
>1 cm of disease remained at the end of the surgical 
procedure. The National statistics office of the 
Republic of Macedonia mortality registry was 
accessed in April 2017 to acquire the exact date of 
death of all patients. The same date was used as a 
cut-off for the surviving patients.  
The data were analysed in a descriptive 
fashion and summary statistics were provided, as 
appropriate. Survival was calculated using the Kaplan-
Meier method. For survival comparison, patients were 
grouped based on age into two groups: (1) 65 years 
and younger; (2) older than 65 years. Patients were 
further stratified in relation to the initial platinum-free 
interval as: (1) highly platinum-sensitive (recurrence 
after at least 12 months after stopping the initial 
adjuvant platinum-based therapy); (2) partially 
platinum, sensitive (recurrence within 6-12 months); 
and platinum resistant (recurrence or progression 
within 6 months of the initial platinum-based therapy). 
Differences in survival were also evaluated for the 
groups of patients with grade 2 and grade 3 tumours. 
The Mantel-Cox log-rank method was used to test for 
statistically significant differences in the survival. All 
statistical calculations were done using IBM SPSS 
Statistics software package, version 23. A probability 
value of p ≤ 0.05 was considered significant.  
 
 
Results 
 
A total of 81 eligible patients were identified 
and included in the study. Table 1 summarises the 
demographic and clinical characteristics of the study 
group.  
Table 1: Summary of patient characteristics 
                      Characteristic  
Age (median, [range]) 60 years [24-78] 
 Tumor grade  
 2 (n, %) 26 (32.1%) 
 3 (n, %) 55 (67.9%) 
Tumor stage  
 IIIA (n, %) 9 (11.1%) 
 IIIB (n, %) 24 (29.6%) 
 IIIC (n, %) 45 (55.6%) 
 IV (n, %) 3 (3.7%) 
Residual disease  
≤1cm (n, %) 29 (35.8%) 
>1cm (n, %) 52 (64.2%) 
Platinum-free interval  
< 6 months 16 (19.8%) 
 6-12 months 24 (29.6%) 
 > 12 months 41 (50.6%) 
 
The median age of the patients was 60 years 
(range 24-78). Twenty-eight (34.6%) patients were 
older than 65 years at the time of diagnosis. The 
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majority of patients, 45 (55.6%), were diagnosed with 
stage IIIC disease at the time of diagnosis, 9 (11.1%) 
patients were staged as IIIA, 24 (29.6%) patients had 
stage IIIB disease, and only 3 (3.7%) patients were 
stage IV. All stage IV patients were classified as stage 
IV by malignant pleural effusion. Twenty-six (32.1%) 
of the neoplasms were grade 2, and 55 (67.9%) were 
grade 3. Optimal debulking was achieved in 29 
patients (35.8%). Forty-one (50.6%) of the patients 
were reported to be highly platinum sensitive, with a 
platinum-free interval larger than 12 months. Thirty-six 
patients (44.4%) from the cohort were still alive at the 
study cross-section point. 
The average overall survival in the studied 
cohort was 46.59 months (95%CI = 39.11-54.06). 
Figure 1 shows the Kaplan-Meier survival function plot 
for the overall survival. 
 
Figure 1: Overall survival of patients with an advanced stage high-
grade serous cancer in the studied cohort 
 
The estimated survival of patients 65 years 
old or younger was 49.18 months (95%CI = 40.85-
57.51), compared to an average survival of 39.03 
months (95%CI = 27.25-50.81) for patients older than 
65 years (Figure 2), but the difference is not 
statistically significant (p = 0.099).  
 
Figure 2: Comparison of survival in the different age groups 
We also failed to document a statistically 
significant difference (p = 0.183) in the survival of 
patients with grade 2 and grade 3 disease, with 
survival averaging at 51.74 months (95%CI = 40.69-
62.78) and 43.03 months (95%CI = 34.01-52.05) for 
grade 2 and grade 3 disease, respectively (Figure 3). 
 
Figure 3: Comparison of survival in patients with grade 2 and grade   
disease 
 
Optimal surgical debulking greatly influenced 
survival in the analysed series of patients. The 
estimated survival of patients that had the 
postoperative residual disease of ≤1cm was 75.55 
months (95%CI = 66.47-84.63), while patients with 
suboptimal surgical debulking (i.e. a postoperative 
residual disease of >1 cm) had an estimated survival 
of 30.78 months (95%CI = 24.14-37.42) (p < 0.001).  
 
Figure 4: Comparison of survival in patients with optimal and 
suboptimal surgical debulking 
 
Platinum sensitivity was also an important 
determinant of survival with estimated survival ranging 
from 8.75 months (95%CI = 6.55-10.95) for patients 
with a platinum-free interval less than 6 month, 27.89 
months (95%CI = 23.38-32.39) for patients with a 
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platinum-free interval of 6-12 months and 67.05 
months (95%CI = 58.83-75.27) for highly platinum-
sensitive patients with a platinum-free interval longer 
than 12 months (p < 0.001). Figure 4 and 5 present 
the Kaplan-Meier plots for both comparisons. 
 
Figure 5: Comparison of survival depending on platinum resistance 
status 
 
 
 
Discussion 
 
In this study, we present the demographic and 
clinical (surgical and treatment-related) factors 
associated with survival in patients treated for 
advanced-stage HGSC in the Republic of Macedonia. 
We analysed the medical data of a total of 81 
advanced stage HGSC patients. Patients with longer 
survival in our series appeared to be younger and 
were likely to have had optimal surgical cytoreduction, 
defined in the study as ≤ 1cm of residual disease. 
Patients that had longer platinum-free intervals also 
had better survival rates. In spite of that, a small 
fraction of patients who either had suboptimal 
debulking or primary platinum resistance achieved 
paradoxically long survival periods.   
Age has been consensually accepted as a 
prognostic factor for ovarian cancer survival [12, 13]. 
Older women have an increased risk of treatment 
failure and hence higher rates of recurrences and 
lower survival rates [14]. In the series of patients 
analysed by Markman et al. [15], the median survival 
for patients younger than 65 years was at least two 
years longer, compared to the median survival of 
patients older than 65 years. Patients in the current 
cohort that were older than 65 years had shorter 
average survival times of ten months, compared to 
patients younger than 65 years, but the difference was 
not statistically significant. The lack of statistical 
significance could be attributed to selection bias 
(advanced stage HGSC patients only) and a small 
sample size.  
The tumour grade, or the degree of cellular 
differentiation, has long been considered a 
determinant of survival. The theory is based on the 
understanding that poorly differentiated cells manifest 
a higher degree of aberrant mitoses, which translates 
into a more aggressive cancer cell behaviour.  
However, published data for the association between 
tumour grade and clinical outcome are conflicting, 
partly as a result of the lack of a universally accepted 
grading system [16, 17].  In the past decade, the well-
established three-tier grading system introduced by 
FIGO in the 1970s that uses cellular architecture as 
the defining characteristic of tumour grade has been 
replaced by a two-tier system based on clinical, 
morphological and molecular studies [18, 19].  Indeed, 
our data showed no difference in survival between 
grades 2 and 3, which was to be expected since all 
grade 2 and grade 3 tumours met contemporary 
criteria to be classified as high-grade tumours.  
The success of cytoreductive surgery, defined 
by the volume of residual disease, has consistently 
been heralded as one of the most significant factors 
influencing both progression-free and overall survival 
[20].  In this study, optimal surgical debulking (defined 
as a residual disease of ≤ 1 cm) more than doubled 
survival; patients that were optimally debulked had an 
estimated mean survival of 75.55 months versus and 
estimated mean survival of 30.78 months for patients 
with postoperative residual disease greater than 1 cm 
(p < 0.001). A Cochrane Database Review, published 
recently [21], was focused on analysing the 
effectiveness of optimal primary cytoreductive surgery 
in patients with advanced stage epithelial ovarian 
cancers. The authors demonstrated that overall 
survival and progression-free survival were 
significantly prolonged in patients who had no grossly 
visible residual disease following primary debulking 
surgery. The beneficial effects were also present in 
the groups of patients with residual diseases of less 
than 1 cm, but only a borderline difference in 
progression-free survival remained when the residual 
disease of more and less than 2 cm was used as the 
basis for patient comparison. Consequently, the 
authors conclude that the aim of every primary 
surgery for advanced-stage epithelial ovarian cancer 
should be complete cytoreduction to no grossly visible 
disease.  
One of the most reliable predictors of 
response to chemotherapy, and consequently 
survival, is the platinum-free interval [15, 22]. This is 
mostly the result of the first-line adjuvant 
chemotherapy for ovarian cancers being relatively 
constant (carboplatin with paclitaxel) over the past two 
decades. Our data also showed that patients with a 
platinum-free interval longer than 12 months survived 
significantly longer (p < 0.001) when compared to 
patients with a platinum-free interval of 6-12 months 
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and less than six months (67.05 months vs. 27.89 
months and 8.75 months, respectively).  
The prognosis in ovarian cancer patients is 
largely a function of disease stage, which represents 
the most important prognostic variable for ovarian 
cancer survival. In the current series, we analysed 
only data from advanced stage patients, in an attempt 
to highlight the prognostic importance of other 
parameters such as tumour characteristics, surgical 
and treatment-related conditions and demographic 
factors. Furthermore, the study was descriptive. 
Recently published studies have focused on the 
significance of molecular features of the tumours as a 
proxy for tumour biology, thus enabling the 
researchers to better predict the response to various 
therapeutic modalities and determine factors 
influencing survival. Our future studies will compare 
this group of patients and compare survival by the 
molecular determinants of the tumour.  
In conclusion, the average overall survival of 
advanced stage HGSC patients in the studied series 
was 46.59 months (95%CI = 39.11-54.06). Patients 
aged 65 years or younger tended to live 
approximately ten months longer than patients older 
than 65 years, but this difference was not statistically 
significant. There was no difference in HGSC survival 
in the groups of patients with grade 2 and grade 3 
diseases. However, optimal surgical debulking and 
platinum sensitivity were associated with significantly 
better overall survival.  
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